IP Library › Granted Patent US 11,702,421
Granted Patent B2
US 11,702,421 · App. 17/352,146 · Granted Jul 18, 2023

Substituted pyridines as irreversible inhibitors of menin-MLL interaction

Inventors: Thomas Butler (Redwood City, CA); Jim Palmer (Warrandyte, AU); Ravi Upasani (San Jose, CA); Matthew Welsch (New Haven, CT); Sridhar Vempati (Edison, NJ); Brendan Kelly (Castlecomer, IE); Edward Painter (Chappaqua, NY)
Assignee: BIOMEA FUSION, LLC
C07D487/04C07D401/04C07D401/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,702,421
App. No.
17/352,146
Granted
Jul 18, 2023
Kind
B2
Abstract

Disclosed herein are heterocyclic compounds according to formula (I) having the structure that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-HLL interaction. Also disclosed are pharmaceutical compositions that include compounds according to formula (I). Methods of using the menin-HLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Claims (8)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2021
From: UPASANI, RAVI; PALMER, JIM; VEMPATI, SRIDHAR; BUTLER, THOMAS; KELLY, BRENDAN; PAINTER, EDWARD; WELSCH, MATTHEW
To: BIOMEA FUSION, LLC
Reel/Frame 057855/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2021
From: BIOMEA FUSION, LLC
To: BIOMEA FUSION, INC.
Reel/Frame 056758/0893 →
Continuity (3)
Continuation 16732226 · Dec 31, 2019
Provisional Application 62786842 · Dec 31, 2018
Related Publication 20220169627A1 · Jun 2, 2022
Cited By (3)
US 12,215,113 US 12,251,385 US 12,275,739